Everything we've seen

1. ·Nov 15, 11:34 AMstreamnews

   GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

   GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

2. ·Nov 15, 11:34 AMstreamnews

   U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

   Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

3. ·Nov 15, 11:19 AMstreamnews

   GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

   GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

4. ·Nov 15, 11:19 AMstreamnews

   U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

   Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

5. ·Nov 15, 11:04 AMstreamnews

   GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

   GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

6. ·Nov 15, 11:04 AMstreamnews

   U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

   Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

7. ·Nov 15, 10:49 AMstreamnews

   GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

   GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

8. ·Nov 15, 10:49 AMstreamnews

   U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

   Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

9. ·Nov 15, 10:34 AMstreamnews

   GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

   GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

10. ·Nov 15, 10:34 AMstreamnews

    U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

    Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

11. ·Nov 15, 10:19 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

12. ·Nov 15, 10:04 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

13. ·Nov 15, 9:49 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

14. ·Nov 15, 9:34 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

15. ·Nov 15, 9:19 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

16. ·Nov 15, 9:04 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

17. ·Nov 15, 8:49 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

18. ·Nov 15, 8:34 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

19. ·Nov 15, 8:19 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

20. ·Nov 15, 8:04 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

21. ·Nov 15, 7:49 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

22. ·Nov 15, 7:34 AMstreamnews

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

23. ❖Nov 13, 10:48 AMnewsvia finnhub

    U.S. Fluoroscopy Systems Market Assessment and Opportunity Forecast 2026-2033 Featuring Intelligence on GE HealthCare, Siemens Healthcare, Philips, Canon Medical Systems, Shimadzu Corp., Dornier MedTech, and UMG / DEL MEDICAL

    Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "U.S. Fluoroscopy Systems Market Size, Share & Trends Analysis Report by Product, Application, End Use, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. fluoroscopy systems market was valued at an estimated USD 163.3 million in 2025 and is projected to reach USD 217.5 million by 2033. The market is expected to expand at a compound annual growth rate of 4.2% from 2026 to 2033, supported by increasing demand fo

24. ❖Nov 13, 10:36 AMnewsvia finnhub

    GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

    GEHC's MAGNUS Neuro Alliance aims to advance neuroscience research, expand MRI applications and develop imaging biomarkers for neurological conditions.

25. ❖Nov 12, 12:45 PMnewsvia finnhub

    GE HealthCare Stock Outlook: Is Wall Street Bullish or Bearish?

    Despite GE HealthCare’s underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

26. ❖Nov 11, 5:20 PMnewsvia finnhub

    GE HealthCare: 3 Key Takeaways for Long-Term Investors

    Multiyear supply contracts and higher-margin product launches may help position the company to sustain margin expansion amid industry chip shortages.

27. ❖Nov 11, 11:37 AMnewsvia finnhub

    ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down

    Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report.

28. ❖Nov 11, 5:27 AMnewsvia finnhub

    Argus Research Maintains Buy on GE HealthCare Techs, Raises Price Target to $110

    Argus Research analyst David Toung maintains GE HealthCare Techs (NASDAQ:GEHC) with a Buy and raises the price target from $85 to $110.

29. ❖Nov 10, 7:45 PMnewsvia finnhub

    Moat Stocks Rebound As Tech Retreats

30. ❖Nov 10, 12:58 PMnewsvia finnhub

    GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS

    GE HealthCare expands Vscan Air's AI capabilities with Lung Guidance and AutoAS, enhancing cardiopulmonary assessments and point-of-care diagnostic support.

31. ❖Nov 10, 12:13 PMnewsvia finnhub

    InfuSystem: Strong Franchise, Weak Entry Point

    InfuSystem Holdings, Inc.'s Wound Care and Patient Services segments show strong growth, but cash collections have been delayed. Click for more on INFU stock.

32. ❖Nov 10, 8:00 AMnewsvia finnhub

    GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience

    CHICAGO, November 10, 2026--GE HealthCare (Nasdaq: GEHC) today announced the intent to establish a collaborative research network focused on advancing neuroscience research leveraging an ultra high-gradient head-only 3.0T MR system1. The MAGNUS2 Neuro Alliance will bring together researchers and clinicians with expertise in neurology, radiology, psychiatry, oncology, and several other subject areas, to explore how high-performance MR imaging may enable new scientific questions and research appro

33. ❖Nov 9, 1:14 PMnewsvia finnhub

    GE HealthCare (GEHC) Raised Full-Year Guidance. Here’s What’s Behind Its Recovery.

    We recently published Forget the High-Beta Hype: 10 ‘Sleep Well at Night’ Stocks to Buy Now, and GE HealthCare Technologies (NASDAQ:GEHC) came in 8th on the list. Yahoo Finance reported that the S&P 500 fell more than 4% on Thursday, November 5, its worst day since the April 2025 tariff crash, erasing roughly $3 trillion […]

34. ❖Nov 9, 7:50 AMnewsvia finnhub

    TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances

    Bio-Techne's Q1 fiscal 2027 earnings and revenues beat estimates, driven by Protein Sciences growth, as its merger with Merck KGaA moves closer to completion.

35. ❖Nov 7, 5:17 PMnewsvia finnhub

    GE HealthCare Technologies (GEHC) Led A $160 Million Cardiac Imaging Investment

    GE HealthCare Technologies (NasdaqGS:GEHC) led Laza Medical's Series B round, raising US$160 million to fund AI-based cardiac imaging. The financing aims to advance robotic imaging systems for cardiac procedures using artificial intelligence tools in clinical workflows. The partners plan broader integration of imaging modalities in cardiac catheterization labs to streamline procedure planning and execution. The Laza Medical Series B led by GE HealthCare only captures part of what this...

36. ❖Nov 6, 10:36 AMnewsvia finnhub

    Tandem Diabetes Care names next CEO

    Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019.

37. ❖Nov 6, 8:08 AMnewsvia finnhub

    Mettler-Toledo Stock Up on Q3 Earnings & Revenue Beat, '26 View Up

    MTD beats Q3 earnings and revenue estimates on strong Asian demand, expands margins and raises its 2026 outlook while projecting growth for 2027.

38. ❖Nov 5, 11:27 AMnewsvia finnhub

    GE HealthCare Unveils Allia Celeo to Advance Interventional Imaging

    GEHC's Allia Celeo launch expands its interventional imaging portfolio with AI-powered precision, flexible workflows and predictive service capabilities.

39. !Nov 5, 11:25 AMsignal

    Agent 1 — Immutable — insufficient_capital

40. ?Nov 5, 10:10 AMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $85.42 > MA150 $67.44 (+26.7%), MA rising, 4.9% off 52w high, vol 0.00× avg

41. ❖Nov 5, 8:15 AMnewsvia finnhub

    Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?

    Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

42. ❖Nov 5, 7:55 AMnewsvia finnhub

    STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View Up

    STERIS beats Q2 fiscal 2027 earnings and revenue estimates, fueled by strong segment growth and margin gains, and raises its full-year adjusted EPS outlook.

43. ❖Nov 5, 5:29 AMnewsvia finnhub

    Laza Medical secures $160m to advance robotic imaging system

    The technology remains under active development and has not received regulatory clearance or approval.

44. ❖Nov 4, 4:05 PMnewsvia finnhub

    Laza Medical Raises Up to $160 Million in Series B Financing Led by GE HealthCare to Advance Intelligent Imaging for Transforming the Cath Lab

    Laza Medical, Inc., a Shifamed portfolio company pioneering AI-powered robotic imaging solutions for cardiac interventions, today announced it has raised up to $160 million in Series B structured financing. GE HealthCare led the round, with participation from returning investors Unorthodox Ventures, PA MedTech, and AMED. The financing will support the company's mission to transform the cardiac catheterization laboratory through intelligent imaging technology designed to simplify procedures, incr

45. ❖Nov 4, 2:32 PMnewsvia finnhub

    Tampa General Hospital Expands Advanced Image-Guided Care in Clinical Hybrid Operating Room Setting With GE HealthCare Allia Moveo

    Tampa General Hospital (TGH) today announced the installation of GE HealthCare's Allia™ Moveo next-generation, image-guided therapy (IGT) solution into a clinical hybrid operating room at its hospital, part of the Tampa Medical & Research District (TMRD).

46. ❖Nov 4, 1:05 PMnewsvia finnhub

    S&P 500 Unusual Volume Movers for Today

    S&P 500 unusual-volume movers today include FIS down 23.74%, DDOG down 13.67%, VRT down 13.34% and CVNA up 8.89%, with several names trading above average volume.

47. ❖Nov 4, 9:00 AMnewsvia finnhub

    GEHC Q3 Earnings Call Highlights Raised Outlook and Margin Risks

    GE HealthCare raises its 2026 earnings outlook on strong Q3 results, but tariff risks, fourth-quarter growth concerns and margin pressures remain in focus.

48. ❖Nov 4, 8:40 AMnewsvia finnhub

    Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View Up

    ZBH beats Q3 earnings and revenue estimates, lifting its 2026 outlook as strong Hips and S.E.T. sales offset weakness in Knees amid margin pressure.

49. ❖Nov 3, 9:14 PMnewsvia finnhub

    Will Earnings And AI Product Launches Change GE HealthCare's (GEHC) Narrative

    GE HealthCare Technologies reported basic and diluted earnings per share from continuing operations of US$1.36 for the third quarter of 2026 and introduced the AI centric Allia Celeo image guiding system alongside new AI assisted Vscan Air ultrasound capabilities. The combination of higher reported earnings per share and new AI powered imaging tools highlights how GE HealthCare Technologies is leaning into higher value diagnostics and workflow efficiency to support operating performance. We...

50. ❖Nov 3, 5:19 PMnewsvia finnhub

    GE HealthCare (GEHC) Stock Looks Like A Bargain After Raised Outlook

    GE HealthCare Technologies has climbed sharply over the past month, and that quick move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock now in a different zone than it was just a few weeks ago, the key issue for investors is how much of the recent excitement is already reflected in the earnings multiple. The stock has advanced about 23.7% over the past month, which puts fresh pressure on the earnings-based valuation to...

51. ❖Nov 3, 4:09 PMnewsvia finnhub

    GE HealthCare Technologies (GEHC) Unveils New Imaging Tools, Is It Still 8% Undervalued?

    GE HealthCare Technologies (GEHC) has drawn fresh attention after unveiling the Allia Celeo ceiling-mounted image guiding system and new AI-assisted features for its Vscan Air handheld ultrasound, highlighting a sharper push into advanced medical imaging workflows. That product push has arrived alongside a sharp shift in sentiment, with GE HealthCare Technologies posting a 1-day share price return of 3.89% and a 30-day share price return of 23.74%. However, the year-to-date share price return...

52. ❖Nov 3, 9:00 AMnewsvia finnhub

    GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments

    CHICAGO, November 03, 2026--GE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air™ handheld ultrasound system: Lung Guidance and AutoAS.1 Designed for clinicians evaluating patients with cardiac and respiratory symptoms at the point of care, these innovations are intended to support consistent lung ultrasound image acquisition and provide additional insights for the assessment of moderate-to-severe aortic stenosis (AS).

53. ❖Nov 3, 8:18 AMnewsvia finnhub

    HSIC Q3 Earnings Beat, Revenues Match, '26 EPS View Up, Stock Down

    Henry Schein beats Q3 earnings estimates, matches revenue forecasts and raises its 2026 EPS outlook, yet shares slip despite strong dental and technology sales.

54. ❖Nov 3, 6:59 AMnewsvia finnhub

    UBS Maintains Neutral on GE HealthCare Techs, Raises Price Target to $80

    UBS analyst Graham Doyle maintains GE HealthCare Techs (NASDAQ:GEHC) with a Neutral and raises the price target from $73 to $80.

55. ?Sep 22, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $66.27 < MA150 $68.52 (-3.3%), MA falling, 26.2% off 52w high, vol 1.20× avg

56. ?Sep 21, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $64.81 < MA150 $68.62 (-5.6%), MA falling, 27.8% off 52w high, vol 1.09× avg

57. ?Sep 18, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $64.13 < MA150 $68.73 (-6.7%), MA falling, 28.6% off 52w high, vol 2.61× avg

58. ?Sep 18, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $64.13 < MA150 $68.73 (-6.7%), MA falling, 28.6% off 52w high, vol 2.61× avg

59. ?Sep 18, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $64.13 < MA150 $68.73 (-6.7%), MA falling, 28.6% off 52w high, vol 2.61× avg

60. ?Sep 17, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $64.44 < MA150 $68.82 (-6.4%), MA falling, 28.2% off 52w high, vol 1.58× avg

61. ?Sep 17, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $64.44 < MA150 $68.82 (-6.4%), MA falling, 28.2% off 52w high, vol 1.58× avg

62. ?Sep 17, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $64.44 < MA150 $68.82 (-6.4%), MA falling, 28.2% off 52w high, vol 1.58× avg

63. ?Sep 16, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $63.50 < MA150 $68.92 (-7.9%), MA falling, 29.3% off 52w high, vol 0.79× avg

64. ?Sep 16, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $63.50 < MA150 $68.92 (-7.9%), MA falling, 29.3% off 52w high, vol 0.79× avg

65. ?Sep 15, 6:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $64.07 < MA150 $69.03 (-7.2%), MA falling, 28.6% off 52w high, vol 1.31× avg

66. ?Sep 15, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — entry

    [not executed — reserve_floor_or_cash] Stage 4: close $64.07 < MA150 $69.03 (-7.2%), MA falling, 28.6% off 52w high, vol 1.31× avg

67. ?Sep 15, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $64.07 < MA150 $69.03 (-7.2%), MA falling, 28.6% off 52w high, vol 1.31× avg

68. ?Sep 14, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $64.25 < MA150 $69.13 (-7.1%), MA falling, 28.4% off 52w high, vol 0.79× avg

69. ?Sep 14, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $64.25 < MA150 $69.13 (-7.1%), MA falling, 28.4% off 52w high, vol 0.79× avg

70. ?Sep 11, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $63.93 < MA150 $69.23 (-7.7%), MA falling, 28.8% off 52w high, vol 0.88× avg

71. ?Sep 10, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 4: close $64.24 < MA150 $69.36 (-7.4%), MA falling, 28.4% off 52w high, vol 1.18× avg

72. ?Sep 10, 6:03 PMdecisionconsidered

    Agent 9 — Bear Equity — entry

    [not executed — reserve_floor_or_cash] Stage 4: close $64.24 < MA150 $69.36 (-7.4%), MA falling, 28.4% off 52w high, vol 1.18× avg

73. ?Sep 10, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $64.24 < MA150 $69.36 (-7.4%), MA falling, 28.4% off 52w high, vol 1.18× avg

74. ?Sep 9, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $65.17 < MA150 $69.48 (-6.2%), MA falling, 27.4% off 52w high, vol 1.12× avg

75. ?Sep 9, 6:03 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $65.17 < MA150 $69.48 (-6.2%), MA falling, 27.4% off 52w high, vol 1.12× avg

76. ?Sep 8, 6:03 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $66.78 < MA150 $69.57 (-4.0%), MA falling, 25.6% off 52w high, vol 1.19× avg

77. ?Sep 4, 6:01 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $68.85 < MA150 $69.66 (-1.2%), MA falling, 23.3% off 52w high, vol 0.89× avg

78. ?Sep 3, 6:03 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $69.71 < MA150 $69.73 (-0.0%), MA falling, 22.3% off 52w high, vol 0.82× avg

79. ?Aug 6, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $70.34 < MA150 $71.10 (-1.1%), MA falling, 21.6% off 52w high, vol 1.09× avg

80. ?Aug 5, 6:01 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $70.25 < MA150 $71.19 (-1.3%), MA falling, 21.7% off 52w high, vol 0.34× avg

81. ?Aug 4, 6:01 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $70.25 < MA150 $71.27 (-1.4%), MA falling, 21.7% off 52w high, vol 0.41× avg

82. ?Aug 3, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $69.71 < MA150 $71.36 (-2.3%), MA falling, 22.3% off 52w high, vol 0.55× avg

83. ?Jul 31, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $68.02 < MA150 $71.45 (-4.8%), MA falling, 24.2% off 52w high, vol 0.81× avg

84. ?Jul 30, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $69.98 < MA150 $71.56 (-2.2%), MA falling, 22.0% off 52w high, vol 1.96× avg

85. ❖Jul 29, 3:05 PMnewsvia finnhub

    These S&P500 stocks are moving in today's session

    Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.

86. ❖Jul 29, 1:32 PMnewsvia finnhub

    GE HealthCare Technologies Inc. Q2 2026 Earnings Call Summary

    Moby summary of GE HealthCare Technologies Inc.'s Q2 2026 earnings call

87. ❖Jul 29, 1:28 PMnewsvia finnhub

    Stock Market Today: Dow Sinks As Fed Rate Decision, Warsh Comments Loom; KLA Tumbles (Live Coverage)

    Stock Market Today: The Dow Jones index drops Wednesday ahead of the Fed decision and Fed Chair Warsh's comments. KLA stock is hit.

88. ❖Jul 29, 1:05 PMnewsvia finnhub

    Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

    In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.

89. ❖Jul 29, 12:35 PMnewsvia finnhub

    Uncover the latest developments among S&P500 stocks in today's session.

    Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

90. ❖Jul 29, 12:09 PMnewsvia finnhub

    Here's Why GE Healthcare Shares Popped Higher Today

    Cost increases have hit the company in 2026, but today's earnings report provides evidence of an oncoming improvement.

91. ❖Jul 29, 11:42 AMnewsvia finnhub

    GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

    GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

92. ❖Jul 29, 11:20 AMnewsvia finnhub

    Stock Market Today: Dow Dives 800 Points As Fed Rate Call Looms; GE HealthCare Soars (Live Coverage)

    Stock Market Today: The Dow Jones index drops Wednesday ahead of the Fed decision and Fed Chair Warsh's comments. SK Hynix sells off.

93. ❖Jul 29, 11:08 AMnewsvia finnhub

    Vertiv, SoFi, GE HealthCare, Micron, SK Hynix, Garmin, and More Stocks That Explain Today’s Market

    FEATURE Stocks were tumbling Wednesday ahead of the Federal Reserve’s decision on interest rates. Garmin was a rare bright spot, surging 16% to lead the The Swiss technology company best known for its navigation hardware and fitness trackers lifted its full-year targets following a surge in demand for the second quarter.

94. ❖Jul 29, 11:05 AMnewsvia finnhub

    S&P 500 Stocks: GEHC Revives, Humana Fades On Earnings

    GE HealthCare Technologies ran at the top of the S&P 500 Wednesday morning, while Humana was among major laggards after both companies posted better-than-expected Q2 earnings signaling a return to profit growth. GEHC broke above its recent trading range that followed its dive on Q1 results. Wednesday's stock action was pretty much the reversal of what we've seen this year for GEHC and HUM, with medical equipment stocks among the market's worst-performing industry groups and managed-care stocks ranked in the top tier.

95. ❖Jul 29, 11:04 AMnewsvia finnhub

    GE HealthCare Technologies Q2 Earnings Call Highlights

    GE HealthCare Technologies (NASDAQ:GEHC) reported second-quarter results marked by strong order growth, a record backlog and continued momentum in its Advanced Imaging Solutions and Pharmaceutical Diagnostics businesses, while Patient Care Solutions remained pressured by operational fulfillment issu

96. ❖Jul 29, 10:35 AMnewsvia finnhub

    Wednesday's session: gap up and gap down stock in the S&P500 index

    Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

97. ❖Jul 29, 8:43 AMnewsvia finnhub

    GE HealthCare Technologies Inc. (GEHC) Q2 2026 Earnings Call Transcript

    GE HealthCare Technologies Inc. (GEHC) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsCarolynne Borders - Chief Investor Relations...

98. ❖Jul 29, 8:35 AMnewsvia finnhub

    Get insights into the top movers in the S&P500 index of Wednesday's pre-market session.

    The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

99. ❖Jul 29, 8:33 AMnewsvia finnhub

    GE HealthCare Beats Second-Quarter Expectations as Record Orders Drive Growth

    GE HealthCare Technologies Inc. (NASDAQ:GEHC) reported stronger-than-expected second-quarter results on Wednesday, with record order growth and revenue exceeding Wall Street forecasts, sending shares about 9% higher in pre-market trading.

100. ❖Jul 29, 7:59 AMnewsvia finnhub

     Stocks Mostly Up Pre-Bell Ahead of Fed Rate Decision, Big Tech Earnings

     The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders

101. ❖Jul 29, 7:34 AMnewsvia finnhub

     GE HealthCare Hits Record Backlog, Stock Jumps

     GE HealthCare (GEHC) stock surged after Q2 earnings beat estimates, driven by strong imaging and diagnostics growth.

102. ❖Jul 29, 7:30 AMnewsvia finnhub

     GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates

     GE HealthCare (GEHC) delivered earnings and revenue surprises of +8.65% and +0.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

103. ❖Jul 29, 7:29 AMnewsvia finnhub

     GE HealthCare Stock Soars After Earnings. Here’s What Drove the Profit Gains.

     GE HealthCare reports earnings per share of $1.13 from sales of $5.3 billion. Wall Street was looking for $1.04 a share and $5.3 billion, respectively.

104. ❖Jul 29, 7:25 AMnewsvia finnhub

     GE HealthCare (NASDAQ:GEHC) Surges on Q2 Earnings Beat

     GE HealthCare Q2 EPS $1.13 beats estimates, revenue in-line at $5.295B. Record orders drive stock 11% higher pre-market. Guidance reaffirmed.

105. ▣Jul 28, 8:00 PMjournalstop

     Agent 9 — Bear Equity closed short 159 @ $71.94 (-$1,495.40)

     intraday stop sweep

106. ?Jul 24, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $60.59 < MA150 $71.99 (-15.8%), MA falling, 32.5% off 52w high, vol 2.69× avg

107. ?Jul 24, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $60.59 < MA150 $71.99 (-15.8%), MA falling, 32.5% off 52w high, vol 2.69× avg

108. ?Jul 15, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $63.22 < MA150 $72.98 (-13.4%), MA falling, 29.6% off 52w high, vol 1.87× avg

109. ?Jul 15, 6:01 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $63.22 < MA150 $72.98 (-13.4%), MA falling, 29.6% off 52w high, vol 1.87× avg

110. ?Jul 14, 6:02 PMdecisionconsidered

     Agent 2 — Adaptive — entry

     [not executed — reserve_floor_or_cash] Stage 4: close $61.66 < MA150 $73.13 (-15.7%), MA falling, 31.3% off 52w high, vol 2.56× avg

111. ?Jul 14, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $61.66 < MA150 $73.13 (-15.7%), MA falling, 31.3% off 52w high, vol 2.56× avg

112. ?Jun 17, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $61.15 < MA150 $74.55 (-18.0%), MA falling, 31.9% off 52w high, vol 1.68× avg

113. ?Jun 3, 10:44 AMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $61.39 < MA150 $75.28 (-18.5%), MA falling, 31.6% off 52w high, vol 0.02× avg

114. ?May 18, 12:18 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $49.40 < MA150 $60.94 (-18.9%), MA falling, 31.2% off 52w high, vol 0.04× avg

115. ?May 18, 12:18 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $49.40 < MA150 $60.94 (-18.9%), MA falling, 31.2% off 52w high, vol 0.04× avg

116. ✓May 12, 2:09 PMdecisionacted

     Agent 9 — Bear Equity — entry

     Stage 4: close $62.53 < MA150 $76.49 (-18.2%), MA falling, 30.3% off 52w high, vol 0.04× avg

117. ?May 12, 12:04 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $61.94 < MA150 $76.49 (-19.0%), MA falling, 31.0% off 52w high, vol 0.02× avg

118. ?May 12, 12:04 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $61.94 < MA150 $76.49 (-19.0%), MA falling, 31.0% off 52w high, vol 0.02× avg

119. ▢May 11, 8:00 PMjournal

     Agent 9 — Bear Equity opened short 159 @ $62.53